10 Mar Ozurdex Improves Vision in Diabetic Patient | Treatment for DME
Patient with legal blindness from diabetic macular edema can now read months after treatment with Ozurdex....
Ozurdex Tag
25 Aug New Treatments for Diabetic Macular Edema | Diabetic Retinopathy
Over the past 2 years, several new treatments have become FDA approved for treating diabetic retinopathy!...
30 Sep Intraocular Drug Delivery Systems Gaining Momentum
Retinal specialists have been using intravitreal injections to treat retinal disease. Sustained release systems are gaining in popularity. Soon, more than retinal disease will be treated with these devices....
01 Sep Iluvien Gets Closer to FDA for Diabetic Retinopathy
Iluvien is a type of drug delivery system that may be FDA approved for treating diabetic retinopathy. Instead of laser treatment, the eye will be injected....
01 Jul Iluvien Treatment for Diabetic Macular Edema
Iluvien nears FDA approval and is likely to be the first injectable,sustained release drug delivery system for the treatment of diabetic macular edema....
03 Mar Mr. Ozurdex's Vision is Sustained
Mr. and Mrs. Ozurdex return after each receiving Ozurdex sustained release systems for separate retinal vein occlusions. Their success seems to vary....
01 Feb "Mrs. Ozurdex" Came Back, She Still Can't See…Yet
Ozurdex is an implantable, biodegradable, device that releases steroids into the eye. I inserted this device in "Mrs. Ozurdex" who has a Central Retinal Vein Occlusion. Will this be helpful?...
22 Jan "Mrs. Ozurdex" Does Not See Well
Treating patients with Central Retinal Vein Occlusions with Ozurdex is FDA approved. The visual results are probably not going to be as good as with BRVO, but there is still every reason to treat....
21 Jan "Mr. Ozurdex" is Seeing Well
Ozurdex has been approved for the treatment of macular swelling caused by retinal vascular problems. In my own practice, Ozurdex is becoming more useful. It signifies the beginning of a new era!...
05 Jan 2010: "Year of the…Drug Delivery System?"
Ophthalmic drug delivery is changing with sustained release technology. Icon Biosciences, Inc., announces their intent to test a new anti-inflammatory extended release eye product. ...
- 1
- 2